Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Non-interventional Study in Patients With Moderate to Severe Active Rheumatoid Arthritis in France Receiving Filgotinib for 2 Years

NCT05323591 is registered in ClinicalTrials.gov with Alfasigma S.p.A. as lead sponsor.

NCT NCT05323591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05323591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Non-interventional Study in Patients With Moderate to Severe Active Rheumatoid Arthritis in France Receiving Filgotinib for 2 Years
Lead sponsor
Alfasigma S.p.A.
Phase
Observational
Overall status
Completed
Start date
May 3, 2022
Completion date
March 30, 2026
Enrollment
155 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis